Medicament for treatment of liver cancer

Abstract

The invention provides a pharmaceutical composition comprising Sorafenib in combination with an inhibitor of a specific kinase inhibitor as a medicament for the treatment or prevention of liver cancer.

1 . Pharmaceutical composition comprising Sorafenib and an inhibitor of the activity of Mapk14 for use as a medicament in the treatment or prevention of liver cancer. 
     
     
         2 . Pharmaceutical composition according to  claim 1 , wherein the inhibitor of the activity of Mapk14 is an siRNA containing an oligonucleotide having a nucleotide sequence hybridizing under physiological conditions to the mRNA encoding Mapk14 of SEQ ID NO: 1365, SEQ ID NO: 1366, SEQ ID NO: 1367 or SEQ ID NO: 1368. 
     
     
         3 . Pharmaceutical composition according to  claim 2 , wherein the oligonucleotide is selected from the group comprising SEQ ID NO: 1 to SEQ ID NO: 1364. 
     
     
         4 . Pharmaceutical composition according to  claim 2 , wherein the oligonucleotide comprises first section in a nucleic acid construct which contains a second section which is reverse complementary to the first section. 
     
     
         5 . Pharmaceutical composition according to  claim 2 , wherein the oligonucleotide is arranged under the control of a promoter in an expression cassette. 
     
     
         6 . Pharmaceutical composition according to  claim 2 , wherein the oligonucleotide is contained in a liposome formulation and/or in a viral vector which is packaged in a viral particle or in a virus-like particle. 
     
     
         7 . Pharmaceutical composition according to  claim 1 , wherein the inhibitor has an IC50 for Mapk14 of at maximum 30 nM. 
     
     
         8 . Pharmaceutical composition according to  claim 7 , wherein the inhibitor is selected from the group consisting of the compounds of table 1 in the specification. 
     
     
         9 . Pharmaceutical composition according to  claim 1 , wherein Sorafenib is contained in a formulation for administration separate from a formulation containing the inhibitor of the activity of Mapk14. 
     
     
         10 . Pharmaceutical composition according to  claim 1 , wherein Sorafenib and the inhibitor of the activity of Mapk14 are contained in one composition. 
     
     
         11 . Pharmaceutical combination for the treatment of or prevention of liver cancer comprising: a pharmaceutical formulation comprising an inhibitor of the activity of Mapk14 and a separate pharmaceutical formulation comprising Sorafenib. 
     
     
         12 . Pharmaceutical combination according to  claim 11 , wherein the pharmaceutical formulation comprising an inhibitor of the activity of Mapk14 is for administration separate from the administration of the pharmaceutical formulation comprising Sorafenib for the treatment or prevention of liver cancer for administration to a patient. 
     
     
         13 . Pharmaceutical combination according to  claim 11 , wherein the inhibitor of the activity of Mapk14 is an siRNA containing an oligonucleotide having a nucleotide sequence hybridizing under physiological conditions to the mRNA encoding Mapk14 of SEQ ID NO: 1365, SEQ ID NO: 1366, SEQ ID NO: 1367 or SEQ ID NO: 1368. 
     
     
         14 . Pharmaceutical combination according to  claim 11 , wherein the inhibitor is selected from the group consisting of the compounds of table 1 in the specification. 
     
     
         15 . Method for treatment or prevention of liver cancer comprising administration of an inhibitor of the activity of Mapk14 in combination with Sorafenib. 
     
     
         16 . Method according to  claim 15 , wherein the inhibitor of the activity of Mapk14 is an siRNA containing an oligonucleotide having a nucleotide sequence hybridizing under physiological conditions to the mRNA encoding Mapk14, the siRNA containing at least one of SEQ ID NO: 1 to SEQ ID NO: 1364, or an inhibitor which is a compound selected from the group consisting of the compounds of table 1 in the specification.